Xtant Medical Holdings, Inc. XTNT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Xtant Medical Holdings, Inc. reported revenue across 5 products and services; the largest, Product, was $115M (-0.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$115Mshare n/a-0.5% yoy
- Orthobiologics$72.9Mshare n/a+9.7% yoy
- Spinal Implant$42.3Mshare n/a-14.3% yoy
- License Revenue$18.7Mshare n/a+1146.5% yoy
- License$18.7Mshare n/a+1146.5% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$122M91.4%+16.0% yoy
- Outside the United States$11.5M8.6%-2.3% yoy
Members sum to the consolidated $134M for this period.
- Product$20.9Mshare n/a-28.7% yoy
- Orthobiologics$15.6Mshare n/a-13.6% yoy
- Spinal Implant$5.28Mshare n/a-52.9% yoy
- Bill And Hold Transactions$100Kshare n/ano prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.